GNPX
Price
$3.45
Change
+$0.10 (+2.99%)
Updated
Sep 14 closing price
Capitalization
2.87M
Intraday BUY SELL Signals
REVB
Price
$0.96
Change
-$0.03 (-3.03%)
Updated
Sep 14 closing price
Capitalization
3.8M
51 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GNPX vs REVB

GNPX vs REVB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GNPX vs. REVB commentary
Sep 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a Hold and REVB is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REVB($3.81M) has a higher market cap than GNPX($2.87M). GNPX has higher P/E ratio than REVB: GNPX (0.10) vs REVB (0.04). REVB YTD gains are higher at: -70.143 vs. GNPX (-91.039). REVB has higher annual earnings (EBITDA): -11.24M vs. GNPX (-15.82M). GNPX has more cash in the bank: 15.2M vs. REVB (11.5M). GNPX has less debt than REVB: GNPX (279K) vs REVB (740K). GNPX (0) and REVB (0) have equivalent revenues.
GNPXREVBGNPX / REVB
Capitalization2.87M3.81M75%
EBITDA-15.82M-11.24M141%
Gain YTD-91.039-70.143130%
P/E Ratio0.100.04288%
Revenue00-
Total Cash15.2M11.5M132%
Total Debt279K740K38%
FUNDAMENTALS RATINGS
GNPX vs REVB: Fundamental Ratings
GNPX
REVB
OUTLOOK RATING
1..100
1077
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9680
P/E GROWTH RATING
1..100
982
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNPX's Valuation (6) in the Pharmaceuticals Major industry is in the same range as REVB (7) in the null industry. This means that GNPX’s stock grew similarly to REVB’s over the last 12 months.

GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as REVB (100) in the null industry. This means that GNPX’s stock grew similarly to REVB’s over the last 12 months.

GNPX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as REVB (100) in the null industry. This means that GNPX’s stock grew similarly to REVB’s over the last 12 months.

REVB's Price Growth Rating (80) in the null industry is in the same range as GNPX (96) in the Pharmaceuticals Major industry. This means that REVB’s stock grew similarly to GNPX’s over the last 12 months.

REVB's P/E Growth Rating (2) in the null industry is significantly better than the same rating for GNPX (98) in the Pharmaceuticals Major industry. This means that REVB’s stock grew significantly faster than GNPX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNPXREVB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
COMPARISON
Comparison
Sep 15, 2026
Stock price -- (GNPX: $3.45 vs. REVB: $0.96)
Brand notoriety: GNPX and REVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNPX: 43% vs. REVB: 27%
Market capitalization -- GNPX: $2.87M vs. REVB: $3.8M
GNPX [@Biotechnology] is valued at $2.87M. REVB’s [@Biotechnology] market capitalization is $3.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $131.68B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNPX’s FA Score shows that 1 FA rating(s) are green while REVB’s FA Score has 2 green FA rating(s).

  • GNPX’s FA Score: 1 green, 4 red.
  • REVB’s FA Score: 2 green, 3 red.
According to our system of comparison, REVB is a better buy in the long-term than GNPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNPX’s TA Score shows that 3 TA indicator(s) are bullish while REVB’s TA Score has 3 bullish TA indicator(s).

  • GNPX’s TA Score: 3 bullish, 2 bearish.
  • REVB’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GNPX is a better buy in the short-term than REVB.

Price Growth

GNPX (@Biotechnology) experienced а -1.43% price change this week, while REVB (@Biotechnology) price change was -4.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.85%. For the same industry, the average monthly price growth was -3.79%, and the average quarterly price growth was +6.70%.

Reported Earning Dates

REVB is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-5.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GNPX
Daily Signal:
Gain/Loss:
REVB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ABM49.590.16
+0.32%
ABM Industries
SFST63.10-0.02
-0.03%
Southern First Bancshares
ULBI5.56-0.04
-0.71%
Ultralife Corp
PAA25.85-0.25
-0.96%
Plains All American Pipeline LP
FCUV5.44-0.26
-4.56%
Focus Universal Inc